A Study of Luspatercept in People With Anemia
NCT07725497
This study is recruiting at 7 US sites in 2 states, according to its ClinicalTrials.gov record last updated .
Summary
The researchers are doing this study to test whether luspatercept works to improve hemoglobin levels in people with anemia caused by chronic kidney disease (CKD). The researchers will also test whether luspatercept is a safe treatment that causes few or mild side effects in participants.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Anemia
- Chronic Kidney Disease
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 2
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Last updated on ClinicalTrials.gov
- October 13, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
New Jersey · 3
- Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities) · Basking Ridge, NJ
- Memorial Sloan Kettering Monmouth (Limited Protocol Activities) · Middletown, NJ
- Memorial Sloan Kettering Bergen (Limited Protocol Activities) · Montvale, NJ
New York · 4
- Memorial Sloan Kettering at Suffolk - Commack (Limited Protocol Activities) · Commack, NY
- Memorial Sloan Kettering Westchester (Limited Protocol Activities) · Harrison, NY
- Memorial Sloan Kettering Cancer Center · New York, NY
- Memorial Sloan Kettering Nassau (Limited Protocol Activities) · Uniondale, NY
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.